Estrogen deficiency has been regarded as the main causative factor in menopausal symptoms and diseases. Here, we show that although estrogen decreases by 90%, a concurrent but inverse change occurs in iron levels during menopausal transition. For example, levels of serum ferritin are increased by two- to threefold from before menopause to after menopause. This observation has led us to hypothesize that, in addition to estrogen deficiency, increased iron as a result of menopause could be a risk factor affecting the health of postmenopausal women. Further studies on iron and menopause are clinically relevant and may provide novel therapeutic treatments. Antioxid. Redox Signal. 11, 2939–2943.
Get full access to this article
View all access options for this article.
References
1.
AdamsBD, LazovaR, AndrewsNC, MilstoneLM. Iron in skin of mice with three etiologies of systemic iron overload. J Invest Dermatol, 125:1200–1205. 2005.
2.
AdewoyeAH, ChenTC, MaQ, McMahonL, MathieuJ, MalabananA, SteinbergMH, HolickMF. Sickle cell bone disease: response to vitamin D and calcium. Am J Hematol, 83:271–274. 2008.
3.
AngelopoulosNG, GoulaAK, PapanikolaouG, TolisG. Osteoporosis in HFE2 juvenile hemochromatosis: a case report and review of the literature. Osteoporos Int, 17:150–155. 2006.
4.
BissettDL, ChatterjeeR, HannonDP. Chronic ultraviolet radiation-induced increase in skin iron and the photoprotective effect of topically applied iron chelators. Photochem Photobiol, 54:215–223. 1991.
5.
BrighamD, BeardJ. Iron and thermoregulation: a review. Crit Rev Food Sci Nutr, 36:747–763. 1996.
6.
ClemonsM, GossP. Estrogen and the risk of breast cancer. N Engl J Med, 344:276–285. 2001.
7.
D'AmelioP, CristofaroMA, TamoneC, MorraE, Di BellaS, IsaiaG, GrimaldiA, GenneroL, GariboldiA, PonzettoA, PescarmonaGP, IsaiaGC. Role of iron metabolism and oxidative damage in postmenopausal bone loss. Bone, 43:1010–1015. 2008.
8.
de VernejoulMC, PointillartA, GolenzerCC, MorieuxC, BielakoffJ, ModrowskiD, MiravetL. Effects of iron overload on bone remodeling in pigs. Am J Pathol, 116:377–384. 1984.
9.
FenskeNA, LoberCW. Structural and functional changes of normal aging skin. J Am Acad Dermatol, 15:571–585. 1986.
10.
FinchCA, BellottiV, StrayS, LipschitzDA, CookJD, PippardMJ, HuebersHA. Plasma ferritin determination as a diagnostic tool. West J Med, 145:657–663. 1986.
11.
GarneroP, Sornay-RenduE, ChapuyMC, DelmasPD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res, 11:337–349. 1996.
12.
GoldEB, SternfeldB, KelseyJL, BrownC, MoutonC, ReameN, SalamoneL, StellatoR. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40–55 years of age. Am J Epidemiol, 152:463–473. 2000.
13.
GruenAB, ZhouJ, MortonKA, MilstoneLM. Photodegraded nifedipine stimulates uptake and retention of iron in human epidermal keratinocytes. J Invest Dermatol, 116:774–777. 2001.
14.
GuggenbuhlP, DeugnierY, BoisdetJF, RollandY, PerdrigerA, PawlotskyY, ChalesG. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int, 16:1809–1814. 2005.
15.
HickeyM, DavisSR, SturdeeDW. Treatment of menopausal symptoms: what shall we do now?Lancet, 366:409–421. 2005.
16.
HuFB. The iron-heart hypothesis: search for the ironclad evidence. JAMA, 297:639–641. 2007.
17.
HuangX. Does iron have a role in breast cancer?Lancet Oncol, 9:803–807. 2008.
18.
IsomuraH, FujieK, ShibataK, InoueN, IizukaT, TakebeG, TakahashiK, NishihiraJ, IzumiH, SakamotoW. Bone metabolism and oxidative stress in postmenopausal rats with iron overload. Toxicology, 197:93–100. 2004.
19.
KatsumataS, TsuboiR, UeharaM, SuzukiK. Dietary iron deficiency decreases serum osteocalcin concentration and bone mineral density in rats. Biosci Biotechnol Biochem, 70:2547–2550. 2006.
20.
LaneJM, SerotaAC, RaphaelB. Osteoporosis: differences and similarities in male and female patients. Orthop Clin North Am, 37:601–609. 2006.
21.
LiuG, MenP, KennerGH, MillerSC. Age-associated iron accumulation in bone: implications for postmenopausal osteoporosis and a new target for prevention and treatment by chelation. Biometals, 19:245–251. 2006.
22.
MacKenzieEL, IwasakiK, TsujiY. Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid Redox Signal, 10:997–1030. 2008.
23.
MedeirosDM, PlattnerA, JenningsD, StoeckerB. Bone morphology, strength and density are compromised in iron-deficient rats and exacerbated by calcium restriction. J Nutr, 132:3135–3141. 2002.
24.
MilmanN. Serum ferritin in Danes: studies of iron status from infancy to old age, during blood donation and pregnancy. Int J Hematol, 63:103–135. 1996.
25.
MilmanN, KirchhoffM. Iron stores in 1359, 30- to 60-year-old Danish women: evaluation by serum ferritin and hemoglobin. Ann Hematol, 64:22–27. 1992.
26.
NakanoM, KawanishiY, KamoharaS, UchidaY, ShiotaM, InatomiY, KomoriT, MiyazawaK, GondoK, YamasawaI. Oxidative DNA damage (8-hydroxydeoxyguanosine) and body iron status: a study on 2507 healthy people. Free Radic Biol Med, 35:826–832. 2003.
27.
NelsonHD. Menopause. Lancet, 371:760–770. 2008.
28.
O'ConnorMI. Sex differences in osteoarthritis of the hip and knee. J Am Acad Orthop Surg, 15,suppl 1:S22–S25. 2007.
29.
ParelmanM, StoeckerB, BakerA, MedeirosD. Iron restriction negatively affects bone in female rats and mineralization of hFOB osteoblast cells. Exp Biol Med (Maywood), 231:378–386. 2006.
30.
PinnVW. A new mosaic for women's health. J Dent Educ, 68:7–14. 2004.
31.
PolteT, TyrrellRM. Involvement of lipid peroxidation and organic peroxides in UVA-induced matrix metalloproteinase-1 expression. Free Radic Biol Med, 36:1566–1574. 2004.
32.
RaafatAM, HofsethLJ, LiS, BennettJM, HaslamSZ. A mouse model to study the effects of hormone replacement therapy on normal mammary gland during menopause: enhanced proliferative response to estrogen in late postmenopausal mice. Endocrinology, 140:2570–2580. 1999.
33.
RavnP, BidstrupM, WasnichRD, DavisJW, McClungMR, BalskeA, CouplandC, SahotaO, KaurA, DaleyM, CizzaG. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study: a randomized, controlled trial. Ann Intern Med, 131:935–942. 1999.
34.
ReizensteinP, SkogE, StigellP. Radio-iron content of epithelium and cell turnover in psoriasis: iron excretion in man, II. Acta Derm Venereol, 48:70–74. 1968.
35.
SarraiM, DuroseauH, D'AugustineJ, MoktanS, BellevueR. Bone mass density in adults with sickle cell disease. Br J Haematol, 136:666–672. 2007.
SullivanJL. Are menstruating women protected from heart disease because of, or in spite of, estrogen? relevance to the iron hypothesis. Am Heart J, 145:190–194. 2003.
38.
SullivanJL. Iron and the sex difference in heart disease risk. Lancet, 1:1293–1294. 1981.
39.
SullivanJL. Iron, plasma antioxidants, and the ‘oxygen radical disease of prematurity’Am J Dis Child, 142:1341–1344. 1988.
40.
SullivanJL. Is stored iron safe?J Lab Clin Med, 144:280–284. 2004.
41.
ValentiL, VarennaM, FracanzaniAL, RossiV, FargionS, SinigagliaL. Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int, 20:549–555. 2009.
42.
WeinbergED. Role of iron in osteoporosis. Pediatr Endocrinol Rev, 6,suppl 1:81–85. 2008.
43.
ZacharskiLR, ChowBK, HowesPS, ShamayevaG, BaronJA, DalmanRL, MalenkaDJ, OzakiCK, LavoriPW. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst, 100:996–1002. 2008.
44.
ZacharskiLR, ChowBK, HowesPS, ShamayevaG, BaronJA, DalmanRL, MalenkaDJ, OzakiCK, LavoriPW. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA, 297:603–610. 2007.
45.
ZacharskiLR, OrnsteinDL, WoloshinS, SchwartzLM. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J, 140:98–104. 2000.
46.
ZimmermannMB, HurrellRF. Nutritional iron deficiency. Lancet, 370:511–520. 2007.
